Ph.D., Chief Executive Officer, Member of the Board of Directors and Co-Founder, Artidis AG
Biography
Marija Plodinec co-founded ARTIDIS AG and in November 2017 became the CEO and a Member of the Board of Directors. She studied physics in Zagreb and received her doctorate in 2010 from the University of Basel. For twelve years, she has driven the development of ARTIDIS, a medical device for fast and early diagnosis of breast cancer based on a unique nanomechanical biomarker, bringing the technology from basic research to the first clinical studies. Marija Plodinec is a recognized expert in the field of physical sciences in oncology and has co-authored important scientific papers and patents in this field. She is also a member of several international organizations focusing on cancer research and its clinical applications. Under her leadership, ARTIDIS fundraised more than 25M USD, successfully completed the large clinical study on 545 patients in Switzerland, grew to +40 FTE and partnered up with leading US pharmaceutical and clinical institutions.
Clinical Dx Showcase:
Artidis AG
ARTIDIS AG is a clinical stage medical technology company developing the first nanotechnology platform for tissue analysis combined with a digital data platform intended for broad use in drug discovery, tissue engineering as well as for rapid diagnostics and personalized treatment optimization.
ARTIDIS: Changing the Paradigm of Tissue Analysis
ARTIDIS: Changing the paradigm of tissue analysis with a novel nanotechnology platform that delivers personalized patient treatment strategies and accelerates drug development.
Session Abstract – PMWC 2022 Silicon Valley
Track 6 - June 28 9.00 A.M.-4.45 P.M.,Track 6 - June 29 3.30 P.M.-3.45 P.M.,Track 6 - June 30 9.00 A.M.-1.15 P.M.
The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative
